DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Information source: National University Hospital, Singapore
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Tuberculosis

Intervention: Faropenem (Drug); Amoxicillin/clavulanic acid 500mg/125mg (Drug); Rifampicin (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: National University Hospital, Singapore

Official(s) and/or principal investigator(s):
Nicholas Paton, Principal Investigator, Affiliation: National University Hospital, Singapore

Overall contact:
Claire Naftalin, Phone: +65 6772 3949, Email: claire_naftalin@nuhs.edu.sg

Summary

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of faropenem boosted with amoxicillin/clavulanic acid. Pharmacokinetics (PK) and Whole blood Bactericidal Activity (WBA) will be measured in healthy volunteers following single doses of faropenem plus amoxicillin/clavulanic acid.

Clinical Details

Official title: Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Cumulative WBA

Secondary outcome: The pharmacokinetic profile of study drug(s)

Detailed description: WBA is an ex vivo model for measuring the combined effects of administered drugs, host factors and strain factors on mycobacterial killing. If performed in parallel with PK measurements, the method can be used to evaluate the effect of drugs throughout the dosing cycle. The aim of this trial is to investigate the bactericidal activity of faropenem administered with amoxicillin/clavulanic acid (augmentin) using the WBA model. We will also explore whether there is any additive effect or synergy with rifampicin in this model. The activity of faropenem on WBA by different strains of M. tuberculosis will be compared and the relationship between the host immune profile and WBA will be assessed.

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Aged 21 and above 2. Male or female willing to comply with the study visits and procedures 3. Willing and able to provide written informed consent Exclusion Criteria: 1. Women who are currently pregnant or breastfeeding 2. Signs of active TB 3. Previous hypersensitivity or allergy to rifampicin, faropenem or other beta-lactam drugs (penicillins, carbapenems) 4. Current use of any drugs or medications known to have an interaction with any of the study drugs 5. Current use of any other drugs, over the counter or herbal preparations that are known or potential inhibitors or inducers of cytochrome P450 enzymes 6. Evidence of renal or hepatic dysfunction or any clinically significant deviation from normal during screening including laboratory determinations 7. Known hepatic disease or alcohol abuse 8. Any other significant condition that would, in the opinion of the investigator, compromise the volunteer's safety or outcome in the trial 9. Current participation in other clinical intervention trial or research protocol

Locations and Contacts

Claire Naftalin, Phone: +65 6772 3949, Email: claire_naftalin@nuhs.edu.sg

National University Hospital, Singapore, Singapore; Recruiting
Claire Naftalin, Phone: +65 6772 3949, Email: claire_naftalin@nuhs.edu.sg
Additional Information

Starting date: February 2015
Last updated: August 4, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017